MCID: CTN007
MIFTS: 62

Cutaneous Leishmaniasis malady

Category: Infectious diseases

Aliases & Classifications for Cutaneous Leishmaniasis

About this section

Aliases & Descriptions for Cutaneous Leishmaniasis:

Name: Cutaneous Leishmaniasis 34 11 13
Asian Desert Cutaneous Leishmaniasis 11 67
Diffuse Cutaneous Leishmaniasis 11 67
Leishmaniasis, Cutaneous 38 67
 
Ethiopian Cutaneous Leishmaniasis 67
Leishmaniasis Diffuse Cutaneous 49
Leishmaniasis Cutaneous 49
Leproid Leishmaniasis 11

Classifications:



External Ids:

Disease Ontology11 DOID:9111
ICD1029 B55.1
SNOMED-CT61 240637006
MeSH38 D016773
NCIt44 C34768

Summaries for Cutaneous Leishmaniasis

About this section
Disease Ontology:11 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions.

MalaCards based summary: Cutaneous Leishmaniasis, also known as asian desert cutaneous leishmaniasis, is related to leishmaniasis and mucocutaneous leishmaniasis. An important gene associated with Cutaneous Leishmaniasis is IFNG (Interferon Gamma), and among its related pathways are African trypanosomiasis and IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drug meglumine has been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related mouse phenotypes are integument and no phenotypic analysis.

Wikipedia:70 Cutaneous leishmaniasis (also known as oriental sore, tropical sore, chiclero ulcer, chiclero\'s ulcer... more...

Related Diseases for Cutaneous Leishmaniasis

About this section

Diseases related to Cutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 307)
idRelated DiseaseScoreTop Affiliating Genes
1leishmaniasis11.9
2mucocutaneous leishmaniasis11.6
3visceral leishmaniasis11.3
4myoclonus epilepsy10.7IFNG, IL4
5piepkorn karp hickok syndrome10.7IL10, TNF
6panner disease10.6IFNG, TNF
7baetz-greenwalt syndrome10.6IFNG, TNF
8motor peripheral neuropathy10.6IFNG, IL4
9myotubular myopathy with abnormal genital development10.6FCER2, IL4
10autoimmune pancreatitis10.6IFNG, TNF
11eye accommodation disease10.6IFNG, IL10, IL4
12thelaziasis10.6IFNG, IL10, IL4
13papillary cystadenocarcinoma10.6IL10, IL13
146q terminal deletion syndrome10.6IL10, IL4, TNF
15hernia of ovary and fallopian tube10.6IFNG, IL10, TNF
16basidiobolomycosis10.6IL10, IL4, TNF
17nevus mucinosis10.6IL10, TLR2
18paralytic lagophthalmos10.6IL10, IL4, TNF
19lymphocytic colitis10.6IFNG, IL4, TNF
20pseudoretinitis pigmentosa10.6IFNG, IL10, TNF
21neurotic excoriation10.6IL10, IL4, TNF
22sensorineural hearing loss10.6IFNG, IL10, TNF
23peripheral t-cell lymphoma10.6IL10, IL4, TNF
24psychologic dyspareunia10.5IFNG, IL10, TNF
25mastocytosis cutaneous with short stature conductive hearing loss and microtia10.5IFNG, IL10, TNF
26hemophagocytic lymphohistiocytosis10.5IFNG, IL10, TNF
27renal cell carcinoma 410.5IFNG, IL4, TNF
28leukostasis10.5IFNG, IL10, TNF
29goat milk allergy10.5IFNG, IL13, IL4
30orbit alveolar rhabdomyosarcoma10.5IFNG, IL10, IL13
31atrichia with papular lesions10.5IFNG, IL4, TNF
32dementia - subcortical10.5IFNG, IL10, TNF
33malignant histiocytosis10.5IFNG, IL4, TNF
34gastric dilatation10.5IFNG, IL10, TNF
35cow milk allergy10.5IL10, IL13, IL4
36bile duct signet ring cell carcinoma10.5IFNG, IL10, TNF
37progressive relapsing multiple sclerosis10.5IFNG, IL10, IL4
38ehlers-danlos syndrome, musculocontractural type10.5IFNG, IL10, TNF
39senile cataract10.5IL10, IL4, TNF
40secondary lacrimal atrophy10.5IFNG, IL4, TNF
41dentinogenesis imperfecta10.5IFNG, IL10, TNF
42pleomorphic lipoma10.5IFNG, IL10, TNF
43eosinophilic gastroenteritis10.5IFNG, IL10, TNF
44sternum lymphoma10.5IFNG, IL10, TNF
45pulmonary systemic sclerosis10.5IFNG, IL10, TNF
46indian tick typhus10.5IFNG, IL13
47personality disorder10.5IFNG, IL10, IL4
48acute hemorrhagic encephalitis10.5FOXP3, IFNG
49decubitus ulcer10.5IL10, IL4, TLR2
50sacral spinal canal and spinal cord meningioma10.5IFNG, IL10, TNF

Graphical network of the top 20 diseases related to Cutaneous Leishmaniasis:



Diseases related to cutaneous leishmaniasis

Symptoms for Cutaneous Leishmaniasis

About this section

Drugs & Therapeutics for Cutaneous Leishmaniasis

About this section

Drugs for Cutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 66)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
2
MiltefosineapprovedPhase 4, Phase 3, Phase 23458066-85-63600
Synonyms:
1-Hexadecylphosphorylcholine
2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt
3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
4-04-00-01460 (Beilstein Handbook Reference)
58066-85-6
AC1L1GAH
BRN 3690495
Baxter Oncology brand of miltefosine
Baxter brand of miltefosine
C039128
C15H32.C7H17NO4P
CHEBI:125047
CHEMBL125
CID3599
Choline hydroxide, hexadecyl hydrogen phosphate, inner salt
Choline phosphate, hexadecyl ester, hydroxide, inner salt
Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI)
Choline, hexadecyl hydrogen phosphate, inner salt
D 18506
D-18506
D02494
D18506
Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt
Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt
H-1850
HDPC
HMS1922D16
HMS2089J15
HePC
Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate
 
Hexadecylphosphocholine
Hexadecylphosphorylcholine
I14-7244
IN1227
Impavido
LS-65132
M-7200
Miltefosin
Miltefosin C
Miltefosina
Miltefosina [INN-Spanish]
Miltefosine
Miltefosine (INN)
Miltefosine [INN:BAN]
Miltefosinum
Miltefosinum [INN-Latin]
Miltex
Miltéfosine
MolPort-003-665-519
Monohexadecylphosphocholine
Monohexadecylphosphorylcholine
NCGC00095169-01
NCGC00095169-02
NCGC00095169-03
NSC605583
Prasfarma brand of miltefosine
SPECTRUM1505329
ST51055612
TF-002
UNII-53EY29W7EC
hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
n-Hexadecylphosphorylcholine
3
Lidocaineapproved, vet_approvedPhase 41226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
4AnthelminticsPhase 4, Phase 2, Phase 1431
5Antimony Sodium GluconatePhase 4, Phase 2, Phase 116
6Antiprotozoal AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11986
7Antiparasitic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12127
8meglumine antimoniatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 126
9Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
10Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
11AnestheticsPhase 49001
12
Nitric OxideapprovedPhase 359910102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
13
Paromomycinapproved, investigationalPhase 3, Phase 2, Early Phase 1291263-89-4, 7542-37-2165580
Synonyms:
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
7542-37-2
84420-34-8
AC1L4WW9
Aminosidin
Aminosidine
Aminosidine, sulfate
C00832
CHEMBL370143
CID165580
Catenulin
Crestomycin
D07467
DB01421
Estomycin
Human .alpha.-1-antitrypsin & Paromomyin
Humatin
Hydroxymycin
Hydroxymycin sulfate
MolPort-002-510-747
Monomycin a
NSC227228
Neomycin E
 
Neomycin e
O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine
PA1-PA2-PA3-PA4
PAROMOMYCIN
PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E
Paramomycin Sulfate
Paramomycin sulfate
Paramomycin sulphate
Paromomicina
Paromomycin (INN)
Paromomycin (TN)
Paromomycin (complex)
Paromomycin I
Paromomycin i
Paromomycin sulfate Rx346208
Paromomycine
Paromomycinum
Paucimycin
Paucimycinum
R 400
R-400
STOCK1N-08708
Zygomycin a1
catenulin
hATT & Paromomycin
paromomycin
14
Imiquimodapproved, investigationalPhase 3, Phase 213899011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
15
Pentoxifyllineapproved, investigationalPhase 2, Phase 3996493-05-64740
Synonyms:
1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion
1-(5-Oxohexyl)-3,7-dimethylxanthine
1-(5-Oxohexyl)theobromine
2a3c
3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl) xantine
3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)xanthine
3,7-Dimethyl-1-(5-oxohexyl)xantine
3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
5-26-14-00081 (Beilstein Handbook Reference)
6493-05-6
AB00052363
AC1L1IUN
AKOS000541484
Agapurin
Agapurin Retard
Azupentat
BAS 00897429
BB_SC-2111
BIDD:GT0174
BL 191
BL-191
BL191
BPBio1_000167
BRD-K57569181-001-05-1
BRN 0558929
BSPBio_000151
BSPBio_003439
C07424
C13H18N4O3
CAS-1677687
CCRIS 6832
CHEMBL628
CID4740
CPD000035998
D00501
D010431
DB00806
Dimethyloxohexylxanthine
DivK1c_000729
Durapental
EHT 0201
EHT-0201
EHT-201
EHT0201
EINECS 229-374-5
EU-0100936
HMS1568H13
HMS1922E16
HMS2051N06
HMS2090H13
HMS2093G21
HMS502E11
Hemovas
I06-1592
IDI1_000729
IN1161
Ikomio
KBio1_000729
KBio2_001924
KBio2_004492
KBio2_007060
KBio3_002942
KBioGR_000893
KBioSS_001924
LS-149385
 
Lopac-P-1784
Lopac0_000936
MLS000079026
MLS000758298
MLS001201764
MolPort-001-823-263
NCGC00015801-01
NCGC00015801-02
NCGC00015801-04
NCGC00015801-10
NCGC00067069-02
NCGC00067069-03
NCGC00067069-04
NCGC00067069-05
NCGC00178062-01
NCGC00178062-02
NINDS_000729
NSC 637086
NSC637086
Oxpentifylline
P 1784
PDSP1_001015
PDSP2_000999
PENTOXYPHYLINE
PNX
Pentoxifilina
Pentoxifilina [INN-Spanish]
Pentoxifyllin
Pentoxifylline
Pentoxifylline (JAN/USP/INN)
Pentoxifylline [USAN:INN:JAN]
Pentoxifyllinum
Pentoxifyllinum [INN-Latin]
Pentoxil
Pentoxil (TN)
Pentoxiphyllin
Pentoxiphylline
Pentoxiphyllium
Pentoxyfylline
Pentoxyphyllin
Pentoxyphylline
Prestwick0_000196
Prestwick1_000196
Prestwick2_000196
Prestwick3_000196
Prestwick_608
Px
Ralofect
Rentylin
SAM001247011
SMR000035998
SPBio_001221
SPBio_002072
SPECTRUM1503611
SR-01000075641-4
STK177321
Spectrum2_001181
Spectrum3_001820
Spectrum4_000227
Spectrum5_001161
Spectrum_001444
Torental
Trental
Trental (TN)
UNII-SD6QCT3TSU
Vasofirin
Vazofirin
ZINC01530776
cis-9-Octadecenoyl coenzyme A
pentoxifylline
16
AzithromycinapprovedPhase 2, Phase 333383905-01-555185, 53477736, 447043
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
121470-24-4
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin Dihydrate
Azithromycin Monohydrate
Azithromycin Sterile
Azithromycin dihydrate
Azithromycin plus Tumor Necrosis Factor
Azithromycine
Azithromycine [French]
Azithromycinum
Azithromycinum [Latin]
Azitrocin
Azitromax
Azitromicina
Azitromicina [Spanish]
Azitromin
Azythromycin
BIDD:GT0792
BRN 5387583
BSPBio_002285
Bio-0676
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP-62993
CP62,993
CPD000471864
DCH3
DRG-0104
 
DivK1c_000233
HMS1922G12
HMS2094M11
HMS500L15
HSDB 7205
Hemomycin
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
LS-1834
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
Misultina
MolPort-002-507-426
N,N-Dimethyl-4-amino-benzaldehyde
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
SAM002589961
SMR000471864
SPBio_001544
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Spectrum_000307
Sumamed
Tromix
UNII-JTE4MNN1MD
XZ-450
Z-Pak
ZIT
Zentavion
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
azithromycin
17
FluconazoleapprovedPhase 317886386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
18
Vitamin Eapproved, nutraceutical, vet_approvedPhase 340659-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
19VaccinesPhase 2, Phase 3, Phase 16428
20Anti-Asthmatic AgentsPhase 33369
21Aluminum sulfatePhase 2, Phase 3, Phase 187
22Bronchodilator AgentsPhase 32856
23Peripheral Nervous System AgentsPhase 322776
24Endothelium-Dependent Relaxing FactorsPhase 3272
25Respiratory System AgentsPhase 34818
26Autonomic AgentsPhase 39774
27Neurotransmitter AgentsPhase 317734
28AntioxidantsPhase 2, Phase 32928
29Radiation-Protective AgentsPhase 2, Phase 3466
30Platelet Aggregation InhibitorsPhase 2, Phase 32419
31interferonsPhase 3, Phase 22137
32Phosphodiesterase InhibitorsPhase 2, Phase 31254
33Vasodilator AgentsPhase 2, Phase 33438
34Protective AgentsPhase 2, Phase 37190
35Adjuvants, ImmunologicPhase 2, Phase 3, Phase 12484
36GentamicinsPhase 3, Phase 2137
37Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Early Phase 110884
38Antibiotics, AntitubercularPhase 3, Phase 26972
39Interferon InducersPhase 3, Phase 2285
40VitaminsPhase 35095
41TocotrienolsPhase 3402
42TocopherolsPhase 3406
43Hormone AntagonistsPhase 312778
44Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 312767
45Steroid Synthesis InhibitorsPhase 31718
46HormonesPhase 313979
47Cytochrome P-450 Enzyme InhibitorsPhase 33822
48Cytochrome P-450 CYP2C9 InhibitorsPhase 3658
49TocopherolNutraceuticalPhase 3406
50TocotrienolNutraceuticalPhase 3402

Interventional clinical trials:

(show top 50)    (show all 82)
idNameStatusNCT IDPhase
1Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous LeishmaniasisCompletedNCT00317980Phase 4
2Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age PatientsCompletedNCT00818818Phase 4
3Pharmacokinetics of Miltefosine in Children and AdultsCompletedNCT01462500Phase 4
4Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in IndiaCompletedNCT01661296Phase 4
5A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)CompletedNCT01975051Phase 4
6Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in ColombiaUnknown statusNCT00487253Phase 3
7Antimony Plus Pentoxifylline in Cutaneous LeishmaniasisCompletedNCT01381055Phase 2, Phase 3
8Add-on Study of Pentoxifylline in Cutaneous LeishmaniasisCompletedNCT01464242Phase 2, Phase 3
9Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)CompletedNCT00606580Phase 3
10Imiquimod Plus Antimony Immunochemotherapy for Cutaneous LeishmaniasisCompletedNCT00257530Phase 3
11Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.CompletedNCT00471705Phase 3
12Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in PanamaCompletedNCT01790659Phase 3
13Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. TropicaCompletedNCT00351520Phase 3
14Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in KabulCompletedNCT00947362Phase 2, Phase 3
15Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to LeishmaninCompletedNCT00429715Phase 2, Phase 3
16Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)CompletedNCT00429780Phase 2, Phase 3
17Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHONCompletedNCT00428727Phase 3
18Miltefosine for Children With PKDLRecruitingNCT02193022Phase 3
19Low Antimonial Dosage in American Mucosal LeishmaniasisRecruitingNCT01301937Phase 2, Phase 3
20Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous LeishmaniasisActive, not recruitingNCT01301924Phase 2, Phase 3
21Miltefosine and GM-CSF in Cutaneous LeishmaniasisNot yet recruitingNCT03023111Phase 3
22High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and ManausTerminatedNCT01953744Phase 3
23Safety and Efficacy of Azithromycin to Treat Cutaneous LeishmaniasisTerminatedNCT00682656Phase 2, Phase 3
24Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous LeishmaniasisTerminatedNCT00317629Phase 3
25Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous LeishmaniasisUnknown statusNCT00840359Phase 2
26Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in BoliviaUnknown statusNCT00537953Phase 2
27Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in PanamaCompletedNCT01083576Phase 2
28Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old WorldCompletedNCT00703924Phase 2
29Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)CompletedNCT01032382Phase 2
30Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)CompletedNCT00600548Phase 2
31WR 279,396 for the Treatment of Cutaneous LeishmaniasisCompletedNCT01988909Phase 2
32Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in ColombiaCompletedNCT01845727Phase 1, Phase 2
33Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisCompletedNCT00973128Phase 2
34Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. GuyanensisCompletedNCT02919605Phase 2
35Miltefosine to Treat Cutaneous Leishmaniasis in BoliviaCompletedNCT00233545Phase 2
36Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous LeishmaniasisCompletedNCT01380314Phase 2
37Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous LeishmaniasisCompletedNCT00884377Phase 2
38A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous LeishmaniasisCompletedNCT01011309Phase 2
39A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous LeishmaniasisCompletedNCT01536795Phase 2
40Intralesional Antimony for Bolivian Cutaneous LeishmaniasisCompletedNCT01300975Phase 2
41Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in BrazilCompletedNCT00004755Phase 2
42Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396CompletedNCT00657917Phase 2
43Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis PatientsCompletedNCT00996463Phase 2
44Miltefosine to Treat Mucocutaneous LeishmaniasisCompletedNCT01050907Phase 2
45Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania ParasiteCompletedNCT00121862Phase 2
46Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test AntigenCompletedNCT00633009Phase 2
47Sodium Stibogluconate Treatment of LeishmaniasisCompletedNCT00662012Phase 2
48Clinical Trial of Miltefosine to Treat Mucosal LeishmaniasisCompletedNCT01377974Phase 2
49Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)CompletedNCT01635777Phase 2
50A Study of a New Leishmania Vaccine Candidate ChAd63-KHRecruitingNCT02894008Phase 2

Search NIH Clinical Center for Cutaneous Leishmaniasis

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: leishmaniasis, cutaneous

Genetic Tests for Cutaneous Leishmaniasis

About this section

Anatomical Context for Cutaneous Leishmaniasis

About this section

MalaCards organs/tissues related to Cutaneous Leishmaniasis:

35
Skin, Testes, T cells, Monocytes, Neutrophil, Thyroid, Placenta

Animal Models for Cutaneous Leishmaniasis or affiliated genes

About this section

MGI Mouse Phenotypes related to Cutaneous Leishmaniasis:

40 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107717.9FOXP3, IFNG, IL10, IL13, IL4, TLR2
2MP:00030127.8FOXP3, GPI, IFNG, IL10, IL13, IL2
3MP:00053797.7FOXP3, IFNG, IL10, IL13, IL2, IL4
4MP:00053907.6IFNG, IL10, IL13, IL4, MPI, PGD
5MP:00020067.5IFNG, IL10, IL2, IL5, SLC11A1, TLR2
6MP:00053897.5FOXP3, IFNG, IL10, IL13, IL2, IL4
7MP:00053706.9FOXP3, GPI, IFNG, IL10, IL2, IL4
8MP:00053886.6FOXP3, GPI, IFNG, IL10, IL13, IL2
9MP:00053846.2FCER2, FOXP3, IFNG, IL10, IL13, IL2
10MP:00053856.1FOXP3, GPI, IFNG, IL10, IL2, MPI
11MP:00053815.9FCER2, FOXP3, IFNG, IL10, IL13, IL2
12MP:00053765.8FCER2, FOXP3, GPI, IFNG, IL10, IL13
13MP:00053875.7FCER2, FOXP3, GPI, IFNG, IL10, IL13
14MP:00053975.6FCER2, FOXP3, GPI, IFNG, IL10, IL13
15MP:00053785.6FOXP3, GPI, IFNG, IL10, IL13, IL2
16MP:00107685.2FCER2, FOXP3, GPI, IFNG, IL10, IL13

Publications for Cutaneous Leishmaniasis

About this section

Articles related to Cutaneous Leishmaniasis:

(show top 50)    (show all 734)
idTitleAuthorsYear
1
A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations. (27109311)
2016
2
Exploratory, Phase II Controlled Trial of Shiunko Ointment Local Application Twice a Day for 4 Weeks in Ethiopian Patients with Localized Cutaneous Leishmaniasis. (27195014)
2016
3
Epidemiologic profile of oriental sore caused by Leishmania parasites in a new endemic focus of cutaneous leishmaniasis, southern Iran. (27605840)
2016
4
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. (27508321)
2016
5
Genetic micro-heterogeneity of Leishmania major in emerging foci of zoonotic cutaneous leishmaniasis in Tunisia. (27137082)
2016
6
An Epidemic Outbreak of Cutaneous Leishmaniasis Presenting as Suppurative Folliculitis: A Study of 6 Cases. (27655127)
2016
7
Zosteriform cutaneous leishmaniasis. (25396096)
2014
8
Rare variants of cutaneous leishmaniasis presenting as eczematous lesions. (25405136)
2014
9
The efficacy of hydro alcoholic extract of Seidlitzia rosmarinus on experimental zoonotic cutaneous leishmaniasis lesions in murine model. (25386402)
2014
10
Pentalinon andrieuxii Root Extract is Effective in the Topical Treatment of Cutaneous Leishmaniasis Caused by Leishmania mexicana. (24347110)
2013
11
LeishmaniaA braziliensis-Reactive T Cells Are Down-Regulated in Long-Term Cured Cutaneous Leishmaniasis, but the Renewal Capacity of T Effector Memory Compartments Is Preserved. (24303052)
2013
12
Cluster of zoonotic cutaneous leishmaniasis (Leishmania major) in European travelers returning from Turkmenistan. (24165385)
2013
13
Cutaneous leishmaniasis with unusual clinical and histological presentation: report of four cases. (23690110)
2013
14
Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. (23390069)
2013
15
Sandflies (Diptera: Psychodidae) in rural and urban environments in an endemic area of cutaneous leishmaniasis in southern Brazil. (23778669)
2013
16
Outbreak of cutaneous leishmaniasis in Fuenlabrada, Madrid. (23567452)
2013
17
Analysis of salivary gland transcripts of the sand fly Lutzomyia ayacuchensis, a vector of Andean-type cutaneous leishmaniasis. (23000112)
2013
18
Cutaneous leishmaniasis acquired in Jura, France. (22257720)
2012
19
First case of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Suriname. (22556081)
2012
20
First molecular detection of Leishmania major within naturally infected Phlebotomus salehi from a zoonotic cutaneous leishmaniasis focus in southern Iran. (22543597)
2012
21
Interleukin-10 and Transforming Growth Factor-I^ in Early and Late Lesions of Patients with Leishmania major Induced Cutaneous Leishmaniasis. (23109957)
2012
22
Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis. (22615508)
2012
23
Cutaneous leishmaniasis in northeastern Brazil: a critical appraisal of studies conducted in State of Pernambuco. (22836662)
2012
24
First report on natural infection of Phlebotomus sergenti with Leishmania promastigotes in the cutaneous leishmaniasis focus in southeastern Tunisia. (21976566)
2011
25
Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. (21747837)
2011
26
Lupoid cutaneous leishmaniasis: a case report. (22984663)
2011
27
Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis. (20818996)
2011
28
Cutaneous leishmaniasis with pseudoepitheliomatous hyperplasia simulating squamous cell carcinoma. (21778837)
2011
29
Leishmania major infection among Psammomys obesus and Meriones shawi: reservoirs of zoonotic cutaneous leishmaniasis in Sidi Bouzid(central Tunisia). (21919726)
2011
30
Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2. (21846836)
2011
31
Sand fly Surveillance within an Emerging Epidemic Focus of Cutaneous Leishmaniasis in Southeastern Iran. (22808384)
2010
32
Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun. (20883265)
2010
33
CD8+ T cells as a source of IFN-I^ production in human cutaneous leishmaniasis. (20967288)
2010
34
Study of sand fly fauna in an endemic area of American cutaneous leishmaniasis and canine visceral leishmaniasis in the municipality of EspA-rito Santo do Pinhal, SALo Paulo, Brazil. (20428683)
2010
35
Eight cases of feline cutaneous leishmaniasis in Texas. (20826847)
2010
36
Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. (20214164)
2010
37
Chemokines and chemokine receptors coordinate the inflammatory immune response in human cutaneous leishmaniasis. (20854864)
2010
38
Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. (20624067)
2010
39
Risk factors for anthroponotic cutaneous Leishmaniasis at the household level in Kabul, Afghanistan. (20351787)
2010
40
Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate. (20663995)
2010
41
Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. (20102417)
2010
42
CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study. (20089160)
2010
43
IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. (19201909)
2009
44
Interleukin 17 production among patients with American cutaneous leishmaniasis. (19476435)
2009
45
Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis. (19560211)
2009
46
Pregnancy enhances the innate immune response in experimental cutaneous leishmaniasis through hormone-modulated nitric oxide production. (18347075)
2008
47
Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. (17951131)
2007
48
Atypical clinical form of cutaneous leishmaniasis: erysipeloid form. (15533066)
2004
49
The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. (9951957)
1999
50
Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis. (8132347)
1994

Variations for Cutaneous Leishmaniasis

About this section

Expression for genes affiliated with Cutaneous Leishmaniasis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cutaneous Leishmaniasis patients vs. healthy controls: 34 (show all 174)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1CXCL9chemokine (C-X-C motif) ligand 9Skin+6.420.000
2CXCL10chemokine (C-X-C motif) ligand 10Skin+6.160.000
3IDO1indoleamine 2,3-dioxygenase 1Skin+5.970.000
4GZMBgranzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)Skin+5.880.000
5GBP5guanylate binding protein 5Skin+5.820.000
6PIPprolactin-induced proteinSkin-5.800.000
7GNLYgranulysinSkin+5.770.000
8MMP1matrix metallopeptidase 1Skin+5.470.000
9DCDdermcidinSkin-5.360.000
10GZMAgranzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)Skin+5.300.000
11SCGB1D2secretoglobin, family 1D, member 2Skin-5.140.000
12CCL8chemokine (C-C motif) ligand 8Skin+5.010.000
13NKG7natural killer cell granule protein 7Skin+4.990.000
14GZMKgranzyme K (granzyme 3; tryptase II)Skin+4.890.000
15SCGB2A2secretoglobin, family 2A, member 2Skin-4.870.000
16IGLL1immunoglobulin lambda-like polypeptide 1Skin+4.820.000
17CCL5chemokine (C-C motif) ligand 5Skin+4.780.000
18MMP3matrix metallopeptidase 3Skin+4.690.000
19CCL3L3chemokine (C-C motif) ligand 3-like 3Skin+4.670.000
20UBDubiquitin DSkin+4.670.000
21ADAMDEC1ADAM-like, decysin 1Skin+4.650.000
22EPSTI1epithelial stromal interaction 1 (breast)Skin+4.530.000
23JCHAINjoining chain of multimeric IgA and IgMSkin+4.530.000
24C5orf46chromosome 5 open reading frame 46Skin-4.530.000
25C1QBcomplement component 1, q subcomponent, B chainSkin+4.510.000
26GZMHgranzyme H (cathepsin G-like 2, protein h-CCPX)Skin+4.480.000
27GBP1guanylate binding protein 1, interferon-inducibleSkin+4.450.000
28CCL4L1chemokine (C-C motif) ligand 4-like 1Skin+4.440.000
29MED27mediator complex subunit 27Skin-4.310.000
30FCER1GFc fragment of IgE, high affinity I, receptor for; gamma polypeptideSkin+4.290.000
31KIR2DL3killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3Skin+4.270.000
32SERPINA12serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12Skin-4.250.000
33GBP4guanylate binding protein 4Skin+4.230.000
34CD8ACD8a moleculeSkin+4.230.000
35TDO2tryptophan 2,3-dioxygenaseSkin+4.190.000
36FCGR1AFc fragment of IgG, high affinity Ia, receptor (CD64)Skin+4.170.000
37CXCL8chemokine (C-X-C motif) ligand 8Skin+4.130.000
38KRT27keratin 27, type ISkin-4.130.000
39DAPL1death associated protein-like 1Skin-4.100.000
40LYZlysozymeSkin+4.100.000
41THRSPthyroid hormone responsiveSkin-4.060.000
42CHP2calcineurin-like EF-hand protein 2Skin-4.030.000
43PRF1perforin 1 (pore forming protein)Skin+4.030.000
44LAG3lymphocyte-activation gene 3Skin+3.990.000
45CYBBcytochrome b-245, beta polypeptideSkin+3.980.000
46WARStryptophanyl-tRNA synthetaseSkin+3.980.000
47CD3DCD3d molecule, delta (CD3-TCR complex)Skin+3.970.000
48IL18BPinterleukin 18 binding proteinSkin+3.960.000
49SNX10sorting nexin 10Skin+3.960.000
50SERPINA1serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1Skin+3.950.000
51FLG2filaggrin family member 2Skin-3.940.000
52RARRES3retinoic acid receptor responder (tazarotene induced) 3Skin+3.940.000
53IL1Binterleukin 1, betaSkin+3.930.000
54FCGR1BFc fragment of IgG, high affinity Ib, receptor (CD64)Skin+3.920.000
55KRT25keratin 25, type ISkin-3.910.000
56S100A7AS100 calcium binding protein A7ASkin+3.910.000
57SLAMF8SLAM family member 8Skin+3.870.000
58PLEKpleckstrinSkin+3.870.000
59C1QCcomplement component 1, q subcomponent, C chainSkin+3.860.000
60KIR2DL4killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4Skin+3.850.000
61CD38CD38 moleculeSkin+3.850.000
62CD2CD2 moleculeSkin+3.840.000
63MMP9matrix metallopeptidase 9Skin+3.840.000
64STAT1signal transducer and activator of transcription 1, 91kDaSkin+3.840.000
65KRT15keratin 15, type ISkin-3.830.000
66CXCL11chemokine (C-X-C motif) ligand 11Skin+3.800.000
67CD7CD7 moleculeSkin+3.800.000
68IFI30interferon, gamma-inducible protein 30Skin+3.770.000
69CD247CD247 moleculeSkin+3.750.000
70CD48CD48 moleculeSkin+3.740.000
71SOD2superoxide dismutase 2, mitochondrialSkin+3.730.000
72LILRB4leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4Skin+3.720.000
73ATP6V1B1ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1Skin-3.680.000
74SLC7A7solute carrier family 7 (amino acid transporter light chain, y+L system), member 7Skin+3.650.000
75SCGB2A1secretoglobin, family 2A, member 1Skin-3.650.000
76IGLL3Pimmunoglobulin lambda-like polypeptide 3, pseudogeneSkin+3.640.000
77IFNGinterferon, gammaSkin+3.640.000
78MT1Hmetallothionein 1HSkin+3.630.000
79SIGLEC10sialic acid binding Ig-like lectin 10Skin+3.630.000
80ISG15ISG15 ubiquitin-like modifierSkin+3.620.000
81LAPTM5lysosomal protein transmembrane 5Skin+3.620.000
82S100A7S100 calcium binding protein A7Skin+3.620.000
83IL7Rinterleukin 7 receptorSkin+3.610.000
84TLR8toll-like receptor 8Skin+3.610.000
85LCE5Alate cornified envelope 5ASkin-3.570.000
86PLAC8placenta-specific 8Skin+3.570.000
87FNDC1fibronectin type III domain containing 1Skin+3.550.000
88KRT77keratin 77, type IISkin-3.540.000
89TGM2transglutaminase 2Skin+3.540.000
90LILRB2leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2Skin+3.530.000
91VSIG8V-set and immunoglobulin domain containing 8Skin-3.530.000
92SPRR2Asmall proline-rich protein 2ASkin+3.530.000
93CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Skin+3.500.000
94CD163CD163 moleculeSkin+3.500.000
95CD53CD53 moleculeSkin+3.490.000
96OAS22'-5'-oligoadenylate synthetase 2, 69/71kDaSkin+3.490.000
97CCL4L2chemokine (C-C motif) ligand 4-like 2Skin+3.470.000
98KYNUkynureninaseSkin+3.470.000
99TNFSF13Btumor necrosis factor (ligand) superfamily, member 13bSkin+3.460.000
100IL4I1interleukin 4 induced 1Skin+3.440.000
101TNFAIP6tumor necrosis factor, alpha-induced protein 6Skin+3.440.000
102SRGNserglycinSkin+3.440.000
103EOMESeomesoderminSkin+3.420.000
104SPP1secreted phosphoprotein 1Skin+3.400.000
105CD14CD14 moleculeSkin+3.390.000
106IL32interleukin 32Skin+3.390.000
107IFI6interferon, alpha-inducible protein 6Skin+3.390.000
108S100A9S100 calcium binding protein A9Skin+3.370.000
109PVRIGpoliovirus receptor related immunoglobulin domain containingSkin+3.350.000
110LILRB3leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3Skin+3.340.000
111FAM26Ffamily with sequence similarity 26, member FSkin+3.330.000
112CXCR6chemokine (C-X-C motif) receptor 6Skin+3.330.000
113RAC2ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)Skin+3.320.000
114SULF1sulfatase 1Skin+3.310.000
115IL37interleukin 37Skin-3.310.000
116LILRA3leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3Skin+3.300.000
117CCR7chemokine (C-C motif) receptor 7Skin+3.290.000
118CORO1Acoronin, actin binding protein, 1ASkin+3.290.000
119AKR1B10aldo-keto reductase family 1, member B10 (aldose reductase)Skin+3.290.000
120FPR1formyl peptide receptor 1Skin+3.280.000
121SLC16A3solute carrier family 16 (monocarboxylate transporter), member 3Skin+3.270.000
122CTLA4cytotoxic T-lymphocyte-associated protein 4Skin+3.270.000
123TYROBPTYRO protein tyrosine kinase binding proteinSkin+3.270.000
124IRF1interferon regulatory factor 1Skin+3.260.000
125MYO1Gmyosin IGSkin+3.260.000
126CD69CD69 moleculeSkin+3.260.000
127C2complement component 2Skin+3.240.000
128ACSBG1acyl-CoA synthetase bubblegum family member 1Skin-3.240.000
129IFIT3interferon-induced protein with tetratricopeptide repeats 3Skin+3.230.000
130SLC2A6solute carrier family 2 (facilitated glucose transporter), member 6Skin+3.220.000
131TSPAN8tetraspanin 8Skin-3.210.000
132IRF8interferon regulatory factor 8Skin+3.210.000
133TNFRSF19tumor necrosis factor receptor superfamily, member 19Skin-3.200.000
134CYBAcytochrome b-245, alpha polypeptideSkin+3.200.000
135FYBFYN binding proteinSkin+3.200.000
136KLRD1killer cell lectin-like receptor subfamily D, member 1Skin+3.180.000
137FABP7fatty acid binding protein 7, brainSkin-3.170.000
138CTSScathepsin SSkin+3.160.000
139FPR3formyl peptide receptor 3Skin+3.160.000
140NCF1Cneutrophil cytosolic factor 1C pseudogeneSkin+3.160.000
141HK3hexokinase 3 (white cell)Skin+3.140.000
142SLC11A1solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1Skin+3.130.000
143CCR1chemokine (C-C motif) receptor 1Skin+3.130.000
144CCL3chemokine (C-C motif) ligand 3Skin+3.130.000
145ISG20interferon stimulated exonuclease gene 20kDaSkin+3.130.000
146HAVCR2hepatitis A virus cellular receptor 2Skin+3.130.000
147SPOCK2sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2Skin+3.130.000
148CD6CD6 moleculeSkin+3.120.000
149CTSZcathepsin ZSkin+3.120.000
150SIGLEC14sialic acid binding Ig-like lectin 14Skin+3.110.000
151PI3peptidase inhibitor 3, skin-derivedSkin+3.110.001
152MT4metallothionein 4Skin-3.110.000
153FCGR2AFc fragment of IgG, low affinity IIa, receptor (CD32)Skin+3.110.000
154IFI44Linterferon-induced protein 44-likeSkin+3.100.000
155PSMB9proteasome subunit beta 9Skin+3.090.000
156DEFB103Bdefensin, beta 103BSkin+3.090.000
157AIF1allograft inflammatory factor 1Skin+3.080.000
158OASL2'-5'-oligoadenylate synthetase-likeSkin+3.080.000
159HCSThematopoietic cell signal transducerSkin+3.080.000
160HCLS1hematopoietic cell-specific Lyn substrate 1Skin+3.070.000
161CD74CD74 molecule, major histocompatibility complex, class II invariant chainSkin+3.070.000
162HAPLN3hyaluronan and proteoglycan link protein 3Skin+3.060.000
163CAMK1Gcalcium/calmodulin-dependent protein kinase IGSkin+3.050.000
164MAMDC2MAM domain containing 2Skin-3.050.000
165TNFRSF6Btumor necrosis factor receptor superfamily, member 6b, decoySkin+3.050.000
166IL24interleukin 24Skin+3.040.000
167FRZBfrizzled-related proteinSkin-3.040.000
168PLIN4perilipin 4Skin-3.030.001
169HLA-DRB1major histocompatibility complex, class II, DR beta 1Skin+3.030.022
170HLA-DQA1major histocompatibility complex, class II, DQ alpha 1Skin+3.030.000
171ITGAXintegrin, alpha X (complement component 3 receptor 4 subunit)Skin+3.020.000
172PLAURplasminogen activator, urokinase receptorSkin+3.020.000
173IL18RAPinterleukin 18 receptor accessory proteinSkin+3.010.000
174CD52CD52 moleculeSkin+3.010.000

Search GEO for disease gene expression data for Cutaneous Leishmaniasis.

Pathways for genes affiliated with Cutaneous Leishmaniasis

About this section

Pathways related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show all 49)
idSuper pathwaysScoreTop Affiliating Genes
19.7IFNG, IL10, TNF
29.7IL13, IL4, IL5
39.4FCER2, IL10, IL4, IL5
49.4IL10, TLR4, TNF
59.4IL10, TLR4, TNF
69.3FCER2, IL4, IL5, TNF
79.2IFNG, IL10, IL2
89.2IFNG, IL13, IL2
99.1FCER2, TLR2, TLR4
109.1IFNG, IL2, TNF
11
Show member pathways
9.1IFNG, IL2, TNF
129.1TLR2, TLR4, TNF
13
Show member pathways
9.0IFNG, IL4, TLR2, TLR4
14
Show member pathways
9.0FOXP3, IL2, IL4
158.9IFNG, IL2, IL4, IL5
168.9IFNG, TLR2, TLR4, TNF
178.9IFNG, TLR2, TLR4, TNF
188.9IFNG, TLR2, TLR4, TNF
198.9IFNG, IL10, IL2, TNF
208.7IFNG, IL10, TLR2, TLR4, TNF
218.7IFNG, IL10, TLR2, TLR4, TNF
228.7IFNG, IL10, TLR2, TLR4, TNF
23
Show member pathways
8.6IFNG, IL4, TLR2, TLR4, TNF
248.6IFNG, IL13, IL2, IL4, IL5
25
Show member pathways
8.6IFNG, IL10, IL2, IL4, TNF
26
Show member pathways
8.4FOXP3, IFNG, IL10, IL2, TNF
27
Show member pathways
8.4IFNG, IL10, IL4, TLR2, TLR4, TNF
28
Show member pathways
8.4IFNG, IL10, IL13, IL2, IL4, IL5
298.4IFNG, IL10, IL13, IL2, IL4, IL5
308.4IFNG, IL10, IL2, IL4, IL5, TNF
31
Show member pathways
8.4IFNG, IL10, IL2, IL4, IL5, TNF
328.3IFNG, IL2, IL4, TLR4, TNF
338.3IL10, IL13, IL2, IL4, IL5, TNF
34
Show member pathways
8.1FOXP3, IFNG, IL2, IL4, IL5, TNF
358.1IFNG, IL10, IL13, IL2, IL4, IL5
36
Show member pathways
8.1IFNG, IL10, IL13, IL2, IL4, IL5
37
Show member pathways
8.1IFNG, IL10, IL13, IL2, IL4, IL5
388.1IFNG, IL10, IL13, IL2, IL4, IL5
39
Show member pathways
8.1IL13, IL2, IL5, TLR2, TLR4
408.0FOXP3, IFNG, IL10, IL13, IL2, IL4
417.9FOXP3, IL10, IL4, IL5, TLR2, TLR4
42
Show member pathways
7.8IFNG, IL10, IL2, TLR2, TLR4, TNF
43
Show member pathways
7.8IFNG, IL10, IL2, TLR2, TLR4, TNF
447.7FOXP3, IFNG, IL10, IL2, IL4, TLR2
45
Show member pathways
7.5IFNG, IL13, IL2, IL4, TLR2, TLR4
46
Show member pathways
7.5FCER2, IFNG, IL2, IL4, TLR2, TLR4
47
Show member pathways
7.3IL10, IL13, IL2, IL4, IL5, TLR2
48
Show member pathways
7.3FCER2, IFNG, IL10, IL13, IL2, IL4
49
Show member pathways
6.6FOXP3, IFNG, IL10, IL13, IL2, IL4

GO Terms for genes affiliated with Cutaneous Leishmaniasis

About this section

Cellular components related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098978.6FCER2, IFNG, IL13, IL4, TLR4, TNF
2extracellular spaceGO:00056157.7GPI, IFNG, IL10, IL13, IL2, IL4

Biological processes related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show all 50)
idNameGO IDScoreTop Affiliating Genes
1regulation of isotype switchingGO:004519110.7IL10, IL4
2negative regulation of complement-dependent cytotoxicityGO:190366010.7IL13, IL4
3positive regulation of killing of cells of other organismGO:005171210.7FCER2, IFNG
4type 2 immune responseGO:004209210.7IL10, IL4
5regulation of proton transportGO:001015510.7IL13, IL4
6positive regulation of vitamin D biosynthetic processGO:006055710.6IFNG, TNF
7positive regulation of calcidiol 1-monooxygenase activityGO:006055910.6IFNG, TNF
8receptor biosynthetic processGO:003280010.6IL10, TNF
9negative regulation of cytokine secretion involved in immune responseGO:000274010.6IL10, TNF
10positive regulation of mononuclear cell migrationGO:007167710.6IL4, TNF
11positive regulation of humoral immune response mediated by circulating immunoglobulinGO:000292510.5FCER2, TNF
12negative regulation of T-helper 17 cell differentiationGO:200032010.5FOXP3, IL4
13positive regulation of interleukin-12 biosynthetic processGO:004508410.4IFNG, TLR4
14negative regulation of endothelial cell apoptotic processGO:200035210.4IL10, IL13, IL4
15positive regulation of chemokine biosynthetic processGO:004508010.4IFNG, IL4, TNF
16negative regulation of chronic inflammatory responseGO:000267710.3FOXP3, IL4
17negative regulation of growth of symbiont in hostGO:004413010.2IFNG, IL10, TNF
18humoral immune responseGO:000695910.2GPI, IFNG, TNF
19protein import into nucleus, translocationGO:000006010.1IFNG, SLC11A1, TNF
20microglial cell activationGO:000177410.0IL13, IL4, TLR2
21defense response to protozoanGO:004283210.0IFNG, IL10, IL4, SLC11A1
22negative regulation of interleukin-17 productionGO:003270010.0FOXP3, IFNG, TLR4
23negative regulation of lymphocyte proliferationGO:00506729.9FOXP3, IL2
24negative regulation of interferon-gamma productionGO:00326899.9FOXP3, IL10, TLR4
25negative regulation of tumor necrosis factor productionGO:00327209.9FOXP3, IL10, TLR4
26positive regulation of MHC class II biosynthetic processGO:00453489.9IFNG, IL10, IL4, TLR4
27positive regulation of interleukin-12 productionGO:00327359.8IFNG, TLR2, TLR4
28positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.8IL10, IL4, IL5, TNF
29positive regulation of isotype switching to IgG isotypesGO:00483049.8IFNG, IL2, IL4
30positive regulation of regulatory T cell differentiationGO:00455919.8FOXP3, IL2
31positive regulation of interleukin-10 productionGO:00327339.8IL4, TLR2, TLR4
32positive regulation of chemokine productionGO:00327229.8TLR2, TLR4, TNF
33positive regulation of tumor necrosis factor productionGO:00327609.8IFNG, TLR2, TLR4
34positive regulation of nitric-oxide synthase biosynthetic processGO:00517709.8FCER2, TLR2, TLR4
35positive regulation of NF-kappaB import into nucleusGO:00423469.7TLR2, TLR4, TNF
36lipopolysaccharide-mediated signaling pathwayGO:00316639.7TLR2, TLR4, TNF
37cellular response to lipopolysaccharideGO:00712229.7IFNG, IL10, TLR4, TNF
38positive regulation of nitric oxide biosynthetic processGO:00454299.6IFNG, TLR4, TNF
39positive regulation of interleukin-6 productionGO:00327559.5TLR2, TLR4, TNF
40negative regulation of interleukin-6 productionGO:00327159.5FOXP3, IL10, TLR4, TNF
41positive regulation of interleukin-8 productionGO:00327579.4TLR2, TLR4, TNF
42defense response to bacteriumGO:00427429.2IFNG, IL10, SLC11A1, TLR4, TNF
43positive regulation of interferon-gamma productionGO:00327299.0IL2, SLC11A1, TLR4, TNF
44positive regulation of transcription, DNA-templatedGO:00458939.0FOXP3, IFNG, IL10, IL4, IL5, TNF
45positive regulation of B cell proliferationGO:00308908.9IL13, IL2, IL4, IL5, TLR4
46response to lipopolysaccharideGO:00324968.9IL10, IL13, SLC11A1, TLR2, TLR4
47inflammatory responseGO:00069548.2IL10, IL13, IL5, SLC11A1, TLR2, TLR4
48positive regulation of gene expressionGO:00106287.9FOXP3, IFNG, SLC11A1, TLR2, TLR4, TNF
49immune responseGO:00069557.7IL10, IL13, IL2, IL4, IL5, TLR2
50positive regulation of transcription from RNA polymerase II promoterGO:00459446.7FOXP3, IFNG, IL10, IL2, IL4, SLC11A1

Molecular functions related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lipopolysaccharide receptor activityGO:000187510.0TLR2, TLR4
2growth factor activityGO:00080838.6GPI, IL10, IL2, IL4, IL5
3cytokine activityGO:00051257.4GPI, IFNG, IL10, IL13, IL2, IL4

Sources for Cutaneous Leishmaniasis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet